Tamayo Louis Edward sold $20K of LXEO

Lexeo Therapeutics (LXEO) stock rose 4.2% pre-market after announcing strategic transactions, including the acquisition of Mantle Therapeutics for up to $21.3M. The deal adds four FA programs to its pipeline, with LX3010 showing early positive data. Lexeo also entered three research collaborations and maintained its cash runway guidance. Raymond James reiterated a Strong Buy rating and $24.00 price target.

Lexeo Therapeutics (NASDAQ:LXEO) shares rose 5.4% premarket after announcing a deal to acquire Mantle Therapeutics for up to $21.3M, expanding its Friedreich ataxia treatment platform. The acquisition includes four therapeutic programs, with $8.3M upfront payment and $13M in potential milestones. Lexeo also launched three research collaborations and expects to submit an IND in 2027. Raymond James reiterated a Strong Buy rating and $24.00 price target.

Lexeo Therapeutics (LXEO) reported Q2 2026 results and updates. It initiated the SUNRISE-FA 2 pivotal trial for LX2006 in June 2026, with first site activated and first patient enrolled. FDA granted RMAT designation for LX2020. Q2 R&D was $19.0M, net loss $25.9M ($0.30/share). Cash was $234.2M. Topline LX2006 data expected 2H 2027.

Lexeo Therapeutics (Nasdaq: LXEO) reported Q2 2026 results and updates. It finalized SUNRISE-FA 2 protocol and SAP for LX2006, with first patient enrolled in June and site activation ongoing. CLARITY-FA enrollment continues. FDA granted RMAT for LX2020. Cash and investments were $234.2M, funding operations into 2028. R&D was $19.0M and net loss $25.9M ($0.30/share).

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated

Lexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, based on interim data from the HEROIC-PKP2 Phase I/II trial. Lexeo also noted Orphan Drug and Fast Track status. RMAT may support accelerated approval, priority review, and rolling review.